Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Prevention mouthrinse safety will be re-reviewed by FDA advisory group.

This article was originally published in The Tan Sheet

Executive Summary

PREVENTION MOUTHRINSE SAFETY RE-REVIEW will come from FDA's Dental Plaque Subcommittee following a motion to table the review of the oral mouthrinse at the group's meeting in Gaithersburg, Md. May 27. The subcommittee had not received six-month clinical trial results prior to its premeeting analysis, subcommittee member Max Listgarten, DDS, University of Pennsylvania, said. Based on information available at the time, however, Listgarten concluded the data for Prevention Labs' Prevention mouthrinse were sufficient to substantiate safety for the ingredient combination (Category I), but insufficient to establish efficacy (Category III).
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS088499

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel